FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Update: 2024-06-21
Description
Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.
Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.
In this episode, we discuss:
- The FDA advisory committee process and its implications for drug approvals
- Functional unblinding and expectancy effects in psychedelic clinical trials
- Potential impacts on the broader psychedelic medicine industry
- The future of psychedelic-assisted psychotherapy protocols
- Neuroplastogen development and non-hallucinogenic approaches
- Challenges around therapy, safety, and regulatory pathways for psychedelic medicines
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
